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Background: National Immunisation Technical Advisory Groups (NITAGs) are multi-disciplinary expert
groups that provide policy-makers with independent, evidence-based advice on vaccination. Between
2008 and 2017, the SIVAC Initiative supported establishment and strengthening of NITAGs in low and
lower-middle income countries though its impact was never assessed quantitatively.
Aim: To quantitatively assess whether SIVAC support is associated with a faster rate at which NITAGs
became functional based on six performance indicators.
Methods: Data from the World Health Organization/Unicef Joint Reporting Form (JRF) from 77 low and
lower-middle-income countries were used to examine the time delay between the start of SIVAC support
and NITAG functionality using a Cox proportional hazards model.
Results: Countries receiving SIVAC support took a mean of 2.00 (95% CI 1.40–2.60) years to reported func-
tionality compared to 2.82 (95% CI 2.05–3.59) years for countries without SIVAC support. We found evi-
dence that SIVAC support is associated with reduced time until NITAG functionality, and this association
cannot fully be explained by GDP per capita, percentage of GDP spent on healthcare, or NITAG function-
ality score at the start of the study period. However, quality of JRF data for the questions used to calculate
NITAG functionality were poor, particularly for countries not receiving SIVAC support.
Conclusion: SIVAC support is likely to have enabled many countries to more rapidly achieve NITAG
functionality.
 2018 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Since the introduction of the Expanded Programme on Immu-
nization in 1974, numerous vaccines have been developed against
life-threatening diseases such as childhood diarrhoea, pneumonia,
meningitis and cervical cancer. Accelerating the introduction of
these vaccines can save lives, particularly in low- and middle-
income countries (LMICs) [1]. However, navigating between
multiple vaccine antigens, formulations, strategies and financing
mechanisms requires careful appraisal of immunological,
epidemiological, economic, logistic and sociological considerations.
To support evidence-based decision making, the World Health
Organization (WHO)’s Global Vaccine Action Plan 2011–2020 calls
for all countries to establish or have access to a National Immuni-
sation Technical Advisory Group (NITAG). NITAGs are multidisci-
plinary expert groups that can provide policy-makers with
independent, evidence-based advice on vaccination [2].
From 2008 to 2017, the Bill & Melinda Gates Foundation funded
the Supporting Independent Immunization and Vaccine Advisory
Committees (SIVAC) Initiative. Hosted by Agence de Médecine
Préventive, SIVAC supported the establishment and strengthening
of NITAGs in low and middle-income countries [3]. While SIVAC
funding ended in August 2017, the impact of its work over the past
decade has not been quantitatively assessed. Qualitative research
indicated that well-functioning NITAGs enhanced national
immunisation programme strength and sustainability through
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providing country-owned evidence-based immunisation decision-
making [4,5]. Hence the aim of our study was to conduct the first
quantitative assessment of the extent to which SIVAC support
expedited the time to which NITAGs became functional. We
focused on 77 countries eligible for support from Gavi, the Vaccine
Alliance, in 2008, since SIVAC was created with a focus on Gavi-
eligible countries.
2. Material and methods
2.1. NITAG functionality
Since 2010, the World Health Organization (WHO) and UNICEF
have requested countries to self-report on six NITAG performance
indicators in their annual Joint Reporting Form (JRF) [6]. These are
listed in Box 1. We obtained responses for these indicators for the
2010–2016 JRFs, for 77 low-income and lower-middle-income
countries that were Gavi-eligible in 2008. Responses were used
to determine whether a NITAG had become functional depending
on the number of questions that were answered with ‘‘Yes”. Differ-
ent answers (i.e. ‘‘No”, ‘‘Not relevant”, missing values) did not con-
tribute to the score.
We defined a NITAG as being functional if all six criteria were
answered with ‘‘yes”. As there were many missing data in the
responses, we also considered an alternative where we restricted
the definition to three key criteria, namely B, C, and D, indicating
a legally-mandated, active NITAG with sufficiently broad member-
ship. We further restricted this so criterion C required only four
rather than at least five expertise areas. We refer to the first defi-
nition as the global definition and the latter as the restricted defi-
nition. In a sensitivity analysis, we explored the effect of using
alternate definitions for NITAG functionality. NITAG functionality
was defined as the year in which the NITAG first became functional
(based on the chosen definition), regardless of whether the score
subsequently decreased.
2.2. SIVAC support
We analysed data from 77 countries eligible for Gavi support in
2008. Out of these countries, using internal SIVAC documents,
2016 JRF data, and Gavi annual reports, we identified countries
that were supported by SIVAC, at least peripherally, at some point
between 2008 and 2017. Countries receive SIVAC support through
a process in which countries are either (i) self-selected by request-
ing support and/or (ii) approached by SIVAC based on their assess-
ment of the country. To estimate support level, we used a simple
summative scoring system of reported SIVAC activities to cate-
gorise the 40 Gavi-eligible countries that SIVAC reported had
received some level of support. First, each support activity was
assigned a weighting from 1 to 4 based on its potential value in
NITAG establishment or strengthening. For example, initial con-
tact, first meeting participation, or introductory training were each
assigned ‘1’. Similar follow-up activities (further meetings and
training participation) were each assigned ‘2’. Finally, more
involved activities that were crucial for establishment/strengthen-
ing, i.e. legal establishment and preparing a work-plan, were each
assigned ‘4’. No ‘3’s were assigned, to maximise differentiation
between countries receiving primarily follow-up versus crucial
support activities. Total scores ranged between 2 and 19, and were
divided into terciles at 10.00 and 2.67, giving high support (10.01–
19.00), medium support (2.68–10.00), and low support (<2.68). As
scoring was only intended as a rough guide, support terciles were
then checked with SIVAC staff to determine appropriateness and
identify anomalies. Countries classified as having low SIVAC sup-
port, but with a support score of 0, were considered to have
received no SIVAC support. This reclassification led to a total of
31 Gavi-eligible countries receiving SIVAC support.
2.3. Statistical analyses
We performed descriptive analyses and Chi-squared tests to see
whether there was a crude association between receiving SIVAC
support and NITAG functionality. Moreover, we used Cox-
proportional hazard models to investigate how SIVAC support
affected time to NITAG functionality (see Supplemental File 2 for
the model specification). Countries were included at the first year
of the study period, and censored with an event in the year their
NITAG became functional. As most countries received SIVAC sup-
port after the study period started, SIVAC support was modelled
as a time-dependent variable. Hence, NITAG-years until receipt of
SIVAC support contribute to the unsupported stratum whilst
NITAG-years since receipt of SIVAC support contribute to the sup-
ported stratum, in order to prevent introduction of immortal time
bias [7]. Similarly, as we are modelling SIVAC support as a time-
dependent variable, we used extended Kaplan-Meier plots to
graphically show rates over time [8].
We assumed that a country must have had at least one year of
SIVAC support for support to have had an effect on time to NITAG
functionality. For instance, SIVAC support in India began in 2013,
but its NITAG also became functional in 2013. Thus, India did not
contribute any NITAG-years to the SIVAC supported stratum in
our survival analyses. Crude rate ratios were adjusted for gross
domestic product (GDP) per capita, proportion of GDP spent on
healthcare, and NITAG functionality score at the start of the study
period. The first two indicators were obtained from the World
Bank’s World Development Indicators for 2015 (http://wdi.world-
bank.org).
2.4. Sensitivity analyses
Apart from presenting results for the global and restricted def-
initions of NITAG functionality, we assessed the sensitivity of our
results against alternative definitions of NITAG functionality,
namely scoring at least one, two, three, four, or five points on the
six criteria mentioned above. We ran an additional analysis on a
subset of the sample, limiting the sample to those Gavi-eligible
Box 1 NITAG performance indicators in the WHO/UNICEF Joint
Reporting Form.
A. Has the advisory group formal written Terms of
References?
B. Are there legislative or administrative basis for the
advisory group?
C. Are members of at least five of the following expertise
areas represented in the group?
1. Paediatricians;
2. Public health experts;
3. Infectious disease experts;
4. Epidemiology experts;
5. Immunology experts;
6. Other experts;
D. Does the advisory group meet at least once per annum?
E. Are the agenda and background documents distributed
(at least 1 week) prior to the meetings?
F. Are members of the advisory group required to disclose
conflict of interest?
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countries (52 out of 77) that reported having a NITAG in JRF 2016.
We did not use this sample in our primary analysis, as it signifi-
cantly reduced the statistical power to detect meaningful effects.
Finally, we assessed the effect of actual SIVAC support categories,
rather than the dichotomous variable of receiving any SIVAC sup-
port. Again, this was not done in our primary analysis, as the num-
ber of countries in some of the support categories was very limited.
3. Results
3.1. Descriptive analyses
Table 1 shows that of 77 included countries, 31 received SIVAC
support and 42 (50) achieved NITAG functionality in 2010–2016
when using the global (restricted) definition. There is some evi-
dence that NITAG functionality is associated with receiving SIVAC
support (v2 = 4.59, p = 0.032) when using the global definition,
and strong evidence (v2 = 9.62, p = 0.002) when using the
restricted definition of NITAG functionality. The year in which each
individual country’s NITAG became functional (under multiple def-
initions of NITAG functionality) and periods in which countries
received SIVAC support, is presented in Supplemental File 1.
Many countries did not answer some or all of the questions
about NITAG functionality. The missing data does not appear to
be random, as SIVAC-supported countries are more likely to have
complete data compared to unsupported countries, especially in
later years. In 2010, the percentage of missing answers was 58%
in countries without SIVAC support, compared to 44% in countries
with SIVAC support (v2 = 15.37, p < 0.001). In 2013, this became
47% compared to 32% (v2 = 19.41, p < 0.001). In 2016, this became
49% compared to 10% (v2 = 138.64, p < 0.001). Data for each year is
presented in Supplemental File 1.
3.2. Time to NITAG functionality
Table 1 shows the average number of years until a country’s
NITAG becomes functional, stratified by SIVAC support. Since
2010, restricting to NITAGs that achieved NITAG functionality in
2010–2016, it took a mean 2.82 (95%CI 2.05–3.59) years to become
functional without SIVAC support, compared to 2.00 (95%CI 1.40–
2.60) years with SIVAC support. Similarly, when assuming that
countries that did not become functional would have become func-
tional at the next possible year (2017), it took on average at least
4.36 (95%CI 3.90–4.82) years to become functional in the absence
of SIVAC support, compared to 2.16 (95%CI 1.57–2.74) years with
SIVAC support.
3.3. Regression analysis
Extended Kaplan-Meier survival estimates are presented in
Fig. 1. SIVAC supported NITAGs seem to have become functional
at a faster rate compared to NITAGs without SIVAC support. Esti-
mated rates and rate ratios are presented in Table 2. There was
strong evidence that the rate at which NITAGs became functional
was higher for countries with SIVAC support (RR 3.68, 95%CI
1.70–7.95, p = 0.001). After adjusting for GDP per capita, percent-
age of GDP spent on healthcare, and NITAG functionality score in
2010, there remains good evidence that NITAGs in SIVAC sup-
ported countries became functional at a faster rate compared to
NITAGs in countries without SIVAC support (RR 2.65, 95%CI 1.16–
6.05, p = 0.021).
3.4. Sensitivity analyses
Results of all sensitivity analyses are presented in Supplemental
File 3. Regardless of how NITAG functionality was defined, there
was good evidence that the rate at which SIVAC supported NITAGs
became functional was considerably higher compared to NITAGs
without SIVAC support.
In one sensitivity analysis, we restricted our sample size to the
52 countries that reported having a functional NITAG in JFR 2016,
i.e. excluding 25 previously included countries, of which 1 received
SIVAC support. Note that 11 of these excluded countries actually
did report having a NITAG at least once prior to 2016. We find sim-
ilar values to the primary analysis for the mean number of years it
takes until NITAGs become functional in each group. However, the
average rate at which NITAGs without SIVAC support become func-
tional is slightly higher, and crude and adjusted rate ratios become
smaller (RR 1.90, 95%CI 0.83–4.34, p = 0.127; adjusted RR 1.77, 95%
CI 0.73–4.27, p = 0.207). Using this restricted sample size, there is
no longer any statistical evidence of a true effect.
When modelling the effect of different SIVAC support categories
(low support; medium support; high support), we only find evi-
dence that NITAGs receiving high SIVAC support became functional
at a faster rate compared to NITAGs without any SIVAC support
(adjusted RR 6.14, 95%CI 2.20–17.15, p-value 0.001). However, it
should be noted that sample sizes in individual SIVAC support cat-
egories were very low.
4. Discussion
Our analysis shows that SIVAC support significantly reduced the
time to NITAG functionality, as defined by JRF criteria. The esti-
mated mean delay between start of SIVAC support and NITAG
functionality, as estimated using either the global or restricted def-
inition, is around 2 years, almost a year shorter compared to
unsupported countries. Similarly, the rate at which NITAGs became
functional was around 3.5 times faster in countries receiving SIVAC
support. Although that association could be partly explained by
GDP per capita, percentage of GDP spent on healthcare, and SIVAC
support score in 2010, the estimated rate remained around 2.5
times higher after adjusting for these covariates. These results hold
Table 1
Number of NITAGs reported as functional in countries eligible for Gavi support in 2008, and mean number of years until functionality, by SIVAC support status.
Definition Without SIVAC support With SIVAC support
Totali Mean (95%CI) Totali Mean (95%CI)
Based on countries achieving NITAG functionality in 2010–2016
Global 20/20 (100%) 2.82 (2.05–3.59) 22/22 (100%) 2.00 (1.40–2.60)
Restricted 23/23 (100%) 3.04 (2.35–3.74) 27/27 (100%) 1.88 (1.05–2.70)
Based on all countriesii
Global 20/46 (43.5%) 4.36 (3.90–4.82) 22/31 (71.0%) 2.16 (1.57–2.74)
Restricted 23/46 (50%) 4.30 (3.82–4.79) 27/31 (87.1%) 2.00 (1.46–2.54)
i Number of countries with a functional NITAG/Total number of countries included.
ii Assuming NITAGs become functional in the first possible year after the study period (i.e. 2017), thereby providing a lower bound on the number of years to functionality.
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when using less stringent definitions of NITAG functionality, as
shown in Supplemental File 3. Supported NITAGs consistently
become functional at a faster rate compared to NITAGs in countries
without SIVAC support.
While SIVAC support was aimed at both development and
strengthening of NITAGs, we only assessed the latter. Although
NITAG development is crucial, only functional NITAGs are likely
to be significant partners in national public health policy-making
processes and we chose to focus on functionality as the most
meaningful outcome. However, evaluation of SIVAC’s full contribu-
tion would also include NITAG establishment. Similarly, we did not
assess cost-effectiveness, as SIVAC support was tailored based on
country needs assessment and thus highly contextual (e.g. some
countries cost more to support due to being more decentralised,
requiring more technical training) and comparing countries was
not always meaningful.
Including countries without a NITAG may impose a selection
bias, as a country needs to have a NITAG in order to become func-
tional. Therefore, we limited our sample to only those countries
reporting a NITAG in JRF 2016 in our sensitivity analysis, decreas-
ing the sample size from 77 to 52 countries. Although our model
still estimates an increased rate of NITAG functionality in SIVAC
supported countries, its confidence interval is too wide and
P-value too large to rule out a chance finding. By limiting our sam-
ple size, we decrease our statistical power to detect an effect.
Moreover, of the 25 countries excluded, 11 reported having a
NITAG in one or more of the JRFs prior to 2016. Therefore, we are
unsure how reliable this answer is to measure NITAG availability
in 2016.
This analysis is consistent with qualitative research showing
that SIVAC-supported countries exhibited satisfactory levels of
functionality e.g. underpinned by clear standard operating proce-
dures, adequate member specialisation, conflict of interest policy,
annual workplans, operational working groups, recommendations
submitted to the Ministry of Health [4,9]. The SIVAC model has
been characterised as a step-by-step approach to establish and/or
strengthen NITAGs, through a combination of tools and technical
support tailored to the local context [3,10]. SIVAC support often
involved direct financing, which though limited in value was often
viewed by NITAGs as catalytic for development. With the ending of
SIVAC and likely fragmentation of institutional support to NITAGs
in LMICs, there is a risk that functionality and further progress will
stall or even reverse [5]. Beyond fulfilling JRF functionality criteria,
NITAGs in Gavi-eligible countries remain fragile and many will
need ongoing strengthening before they can embed themselves
sustainably within national decision-making processes. A more
Table 2
Average rate, and crude and adjusted rate ratios for the association between receipt of SIVAC support and rate of NITAG functionality in countries eligible for Gavi support in 2008.
Figures adjusted for GDP per capita, percentage of GDP spent on healthcare and SIVAC support score in 2010. p-values are derived fromWald-tests, and relate to the adjusted rate-
ratios reported.
Definition Stratum Rate (95%CI) RR (95%CI) Adjusted RR (95%CI) P-value
Global Without SIVAC 0.08 (0.05–0.12) 3.68 (1.70–7.95) 2.65 (1.16–6.05) 0.021
With SIVAC 0.27 (0.15–0.48)
Restricted Without SIVAC 0.10 (0.06–0.14) 3.53 (1.49–8.36) 2.65 (1.37–8.93) 0.009
With SIVAC 0.33 (0.17–0.67)
Fig. 1. NITAG functionality by SIVAC support status. Extended Kaplan-Meier survival plot, showing failure curves of two hypothetical cohorts if SIVAC support status would
not change throughout the follow-up period. Here, failure relates to the proportion of NITAGs that are functional under the global definition. The group size table shows the
number of countries included within each stratum at each time point of the analysis.
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meaningful way than JRF criteria for assessing functionality might
be evaluation of NITAG process and output quality (e.g., national
adoption of vaccine recommendations, long-term NITAG inputs
into national immunisation programme strategies). For example,
a key difference between well-functioning and poorly-
functioning NITAGs was the capacity to consider cost-
effectiveness and funding sustainability within vaccine recommen-
dations [4,5,11].
4.1. Limitations
There are several limitations to this analysis. First, questions
about NITAGs in Joint Reporting Forms were self-reported and
not verified by independent monitors. There was a considerable
amount of missing answers to multiple questions used to compute
NITAG functionality scores, and there was evidence that missing
data were more pronounced for countries without SIVAC-support
than countries with SIVAC support. This may underestimate the
number of countries achieving NITAG functionality without SIVAC
support, especially when more stringent definitions for NITAG
functionality are used. We used alternative definitions for NITAG
functionality to partly overcome this issue. Moreover, the reason
that data quality improved for SIVAC supported countries may be
itself an indicator that functionality of those NITAGs improved.
Second, we assumed that NITAGs became functional in the first
year in which the required NITAG functionality score for a given
definition was met. In some countries, NITAG functionality scores
subsequently decreased, which might be a result of missing data,
but may also reflect that NITAG functionality was not sustainable.
Third, the study period (2010–2016) for which data were avail-
able was relatively short. A longer period, or more detailed data,
may have given a better view for the exact time-delay for countries
that did not achieve NITAG functionality in this analysis.
Fourth, sample sizes in specific SIVAC-support categories were
low, resulting in large confidence intervals. Irrespective of statisti-
cal power, point estimates in each support category still pointed to
a signal of increased rates in all SIVAC-support categories. There
does not seem to be sufficient statistical power to investigate the
effect of individual support categories.
Fifth, countries were predominantly self-selected, rather than
being randomly assigned whether they received SIVAC support or
not. This may impose a selection bias, as countries receiving tech-
nical support may have been more likely to develop a functional
NITAG even in the absence of SIVAC support. Countries receiving
SIVAC support were indeed more likely to have answered the
NITAG-performance indicators mentioned in box 1, even prior to
receipt of SIVAC support. We aimed to mitigate this effect in our
analysis, by adjusting for countries’ NITAG functionality scores at
the start of the study period in our analyses.
Finally, while rate ratios were adjusted for GDP per capita, per-
centage of GDP spent on healthcare, and NITAG functionality score
at the start of the study period, the observed effects may have been
subject to residual confounding by factors that were beyond the
scope of the study to quantify, such as political climate or immuni-
sation programme functionality.
5. Conclusions
Overall, SIVAC support significantly accelerated the time to
functionality for NITAGs. Functional NITAGs are important, as they
provide independent evidence-informed decision-making for
national immunisation programmes. Despite the success of SIVAC
support, 25 of the 77 countries included in this analysis still did
not report being functional in 2016, according to JRF criteria. Given
the successes of SIVAC, a successor may help those countries estab-
lish functional NITAGs. Moreover, NITAG functionality should be
regularly monitored, to determine whether NITAGs remain func-
tional now SIVAC support has ended.
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